Understanding Your Diagnosis: Chronic Visceral ASMD

Receiving a diagnosis of a rare condition like Chronic Visceral Acid Sphingomyelinase Deficiency (ASMD) can feel overwhelming ^[1]. Whether this news comes in infancy, childhood, or later in adulthood, it marks the beginning of a journey toward understanding a complex and unique biological process. While you may have previously heard this condition called Niemann-Pick Disease Type B, medical experts now use the term ASMD to more accurately describe the underlying cause of the disease ^[2].

What is Chronic Visceral ASMD?

Chronic Visceral ASMD is a rare, autosomal recessive genetic disorder ^[2]. This means that for a person to be affected, they must inherit two pathogenic variants (mutations) in the SMPD1 gene—one from each parent ^[3]. Because it is so rare, many healthcare providers may never have seen a case before. Estimates suggest that ASMD affects roughly 0.4 to 0.6 people out of every 100,000 live births, though these numbers can vary significantly depending on the population and the methods used to count cases ^[4][5].

The Biological Cause: The “Recycling” Problem

To understand ASMD, it helps to think of your cells as having a recycling center called the lysosome. Inside the lysosome, specialized proteins called enzymes break down waste products so the cell can stay healthy.

In ASMD, the body does not produce enough of an enzyme called acid sphingomyelinase (ASM) ^[3]. This enzyme has one specific job: breaking down a fatty substance called sphingomyelin ^[6]. When ASM is missing or not working correctly:

1. Accumulation: Sphingomyelin begins to build up inside the lysosomes of cells throughout the body ^[3].
2. Foam Cells: Large immune cells called macrophages become engorged with this fat, taking on a “foamy” appearance under a microscope.
3. Organ Impact: These fat-laden cells accumulate in vital organs—most commonly the liver, spleen, and lungs—causing them to enlarge or lose function over time ^[7][8].

Understanding the ASMD Continuum

Doctors now view ASMD as a continuum (a spectrum) rather than separate, unrelated diseases ^[2]. Where a person sits on this spectrum depends largely on how much enzyme activity they have and which specific pathogenic variants are present in their SMPD1 gene ^[9]. While genotype and residual enzyme activity may provide context, they do not reliably predict an individual’s exact course—your clinical symptoms matter most.

• Infantile Neurovisceral ASMD (Historical Type A): The most severe form, typically appearing in infancy with rapid involvement of the brain and nervous system ^[7].
• Chronic Neurovisceral ASMD (Historical Type A/B): An intermediate form where patients have organ involvement and some degree of neurological symptoms that progress more slowly than the infantile form ^[10].
• Chronic Visceral ASMD (Historical Type B): This is likely the diagnosis you are exploring. It is defined as being predominantly visceral, meaning it affects the internal organs (liver, spleen, lungs) with little to no progressive involvement of the brain or nervous system, though clinical categories can overlap ^[1][7].

Looking Ahead

Because Chronic Visceral ASMD is a spectrum, no two people will have the exact same experience. Some may have very mild symptoms that go unnoticed for years, while others may experience significant organ enlargement or lung issues earlier in life ^[8].

Navigating a rare disease requires a specialized care team, often led by a metabolic specialist or geneticist who can monitor organ health and discuss modern management options. A genetic counselor is a vital part of this team; they can explain your specific SMPD1 variants, coordinate carrier testing for relatives, and discuss reproductive risks ^[11][12].

(Note for families: Observational studies and clinical registries, such as NCT06192576 for younger patients, are sometimes available. Participation is optional and study status changes frequently. Check with your care team or clinicaltrials.gov for current eligibility.) [NCT06192576]